Did the FTC have a good rea­son to block the Sanofi-Maze deal?

Walls of redac­tions in the Fed­er­al Trade Com­mis­sion com­plaint tar­get­ing Sanofi’s deal with Maze Ther­a­peu­tics hold a vi­tal ques­tion for the bio­phar­ma in­dus­try: Was there a smok­ing gun show­ing Sanofi en­gaged in an­ti­com­pet­i­tive be­hav­ior?

The FTC com­plaint im­plies — but doesn’t pub­licly show — the an­swer. An­titrust ex­perts in­ter­viewed by End­points News said that what seems like a sur­pris­ing ac­tion was pack­aged in a more con­ven­tion­al le­gal the­o­ry than an ear­li­er FTC at­tempt to block a phar­ma­ceu­ti­cal deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER